4D Molecular Therapeutics’ (FDMT) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $36.00 target price on the stock.

Several other analysts have also recently issued reports on FDMT. Leerink Partners reaffirmed an “outperform” rating and set a $36.00 price objective (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Cantor Fitzgerald cut 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. BMO Capital Markets lowered their price objective on 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating on the stock in a research note on Thursday, July 18th. Chardan Capital raised their target price on 4D Molecular Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Finally, Royal Bank of Canada lowered their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

4D Molecular Therapeutics Trading Up 12.3 %

FDMT traded up $0.99 during trading on Thursday, hitting $9.01. The company’s stock had a trading volume of 862,469 shares, compared to its average volume of 890,531. The firm has a market capitalization of $468.25 million, a price-to-earnings ratio of -3.16 and a beta of 2.82. The business’s fifty day simple moving average is $10.43 and its 200 day simple moving average is $17.24. 4D Molecular Therapeutics has a twelve month low of $7.32 and a twelve month high of $36.25.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC grew its position in shares of 4D Molecular Therapeutics by 702.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock valued at $110,000 after purchasing an additional 3,026 shares during the last quarter. nVerses Capital LLC purchased a new stake in 4D Molecular Therapeutics in the 3rd quarter worth approximately $40,000. Values First Advisors Inc. acquired a new position in 4D Molecular Therapeutics in the 3rd quarter valued at $57,000. Quest Partners LLC lifted its stake in shares of 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after purchasing an additional 5,745 shares during the period. Finally, Entropy Technologies LP acquired a new stake in shares of 4D Molecular Therapeutics during the first quarter worth $239,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.